Gastroenterology, Klinikum Ludwigsburg, Ludwigsburg, Germany.
Gastroenterology, University of Marburg, Marburg, Germany.
Gut. 2022 Jul;71(7):1251-1258. doi: 10.1136/gutjnl-2021-325300. Epub 2022 Mar 23.
Acute non-variceal upper gastrointestinal bleeding (NVUGIB) is managed by standard endoscopic combination therapy, but a few cases remain difficult and carry a high risk of persistent or recurrent bleeding. The aim of our study was to compare first-line over-the-scope-clips (OTSC) therapy with standard endoscopic treatment in these selected patients.
We conducted a prospective, randomised, controlled, multicentre study (NCT03331224). Patients with endoscopic evidence of acute NVUGIB and high risk of rebleeding (defined as complete Rockall Score ≥7) were included. Primary endpoint was clinical success defined as successful endoscopic haemostasis without evidence of recurrent bleeding.
246 patients were screened and 100 patients were finally randomised (mean of 5 cases/centre and year; 70% male, 30% female, mean age 78 years; OTSC group n=48, standard group n=52). All but one case in the standard group were treated with conventional clips. Clinical success was 91.7% (n=44) in the OTSC group compared with 73.1% (n=38) in the ST group (p=0.019), with persistent bleeding occurring in 0 vs 6 in the OTSC versus standard group (p=0.027), all of the latter being successfully managed by rescue therapy with OTSC. Recurrent bleeding was observed in four patients (8.3%) in the OTSC group and in eight patients (15.4%) in the standard group (p=0.362).
OTSC therapy appears to be superior to standard treatment with clips when used by trained physicians for selected cases of primary therapy of NVUGIB with high risk of rebleeding. Further studies are necessary with regards to patient selection to identify subgroups benefiting most from OTSC haemostasis.
NCT03331224.
急性非静脉曲张性上消化道出血(NVUGIB)采用标准内镜联合治疗,但仍有少数病例较为棘手,且再出血风险较高。本研究旨在比较这些选定患者中一线内镜套扎器(OTSC)治疗与标准内镜治疗的效果。
我们开展了一项前瞻性、随机、对照、多中心研究(NCT03331224)。纳入标准为内镜检查提示急性 NVUGIB 且再出血风险高(定义为完全 Rockall 评分≥7)的患者。主要终点为临床成功,定义为内镜止血成功且无再出血证据。
共筛选了 246 例患者,最终纳入 100 例(平均每个中心和每年 5 例;70%为男性,30%为女性,平均年龄 78 岁;OTSC 组 48 例,标准组 52 例)。标准组所有患者均采用传统夹闭治疗,除 1 例外。OTSC 组的临床成功率为 91.7%(n=44),标准组为 73.1%(n=38)(p=0.019),OTSC 组无持续性出血(0 vs 标准组 6 例,p=0.027),后者均通过 OTSC 抢救治疗成功。OTSC 组有 4 例(8.3%)和标准组有 8 例(15.4%)患者出现再出血(p=0.362)。
对于高危再出血的 NVUGIB 患者,接受过培训的医生采用 OTSC 治疗时,该治疗似乎优于标准夹闭治疗。进一步的研究需要关注患者选择,以确定最受益于 OTSC 止血的亚组。
NCT03331224。